UPDATE – Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement